Merckâ€™s Q4 2009 earnings reflect strong sales growth and successful integration of the Schering-Plough merger, highlighting robust performance in key brands and strategic investments in R&D. However, the cautious outlook for 2010 due to significant patent expirations and anticipated generic competition may temper investor enthusiasm in the short term.

[0]